Systems Biology and Biomarkers of Early Effects for Occupational Exposure Limit Setting

In a recent National Research Council document, new strategies for risk assessment were described to enable more accurate and quicker assessments.(1) This report suggested that evaluating individual responses through increased use of bio-monitoring could improve dose-response estimations. Identi-fication of specific biomarkers may be useful for diagnostics or risk prediction as they have the potential to improve exposure assessments. This paper discusses systems biology, biomarkers of effect, and computational toxicology approaches and their relevance to the occupational exposure limit setting process. The systems biology approach evaluates the integration of biological processes and how disruption of these processes by chemicals or other hazards affects disease outcomes. This type of approach could provide information used in delineating the mode of action of the response or toxicity, and may be useful to define the low adverse and no adverse effect levels. Biomarkers of effect are changes measured in biological systems and are considered to be preclinical in nature. Advances in computational methods and experimental -omics methods that allow the simultaneous measurement of families of macromolecules such as DNA, RNA, and proteins in a single analysis have made these systems approaches feasible for broad application. The utility of the information for risk assessments from -omics approaches has shown promise and can provide information on mode of action and dose-response relationships. As these techniques evolve, estimation of internal dose and response biomarkers will be a critical test of these new technologies for application in risk assessment strategies. While proof of concept studies have been conducted that provide evidence of their value, challenges with standardization and harmonization still need to be overcome before these methods are used routinely.

[1]  K. Wallace,et al.  Dose response considerations in risk assessment--an overview of recent ILSI activities. , 2008, Toxicology letters.

[2]  Michael B. Black,et al.  A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  C. Wild Complementing the Genome with an “Exposome”: The Outstanding Challenge of Environmental Exposure Measurement in Molecular Epidemiology , 2005, Cancer Epidemiology Biomarkers & Prevention.

[4]  Michael B. Black,et al.  Cross-species comparisons of transcriptomic alterations in human and rat primary hepatocytes exposed to 2,3,7,8-tetrachlorodibenzo-p-dioxin. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[5]  A. Hubbard,et al.  Toxicogenomic profiling of chemically exposed humans in risk assessment. , 2010, Mutation research.

[6]  Conrad Brunk,et al.  Guidelines for the communication of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. , 2008, Regulatory toxicology and pharmacology : RTP.

[7]  David M. Reif,et al.  Endocrine Profiling and Prioritization of Environmental Chemicals Using ToxCast Data , 2010, Environmental health perspectives.

[8]  F Kalberlah,et al.  Time extrapolation and interspecies extrapolation for locally acting substances in case of limited toxicological data. , 2002, The Annals of occupational hygiene.

[9]  R. Scheuplein,et al.  Differential Sensitivity of Children and Adults to Chemical Toxicity , 2004, Human and Ecological Risk Assessment: An International Journal.

[10]  I. Rusyn,et al.  Computational Toxicology: Realizing the Promise of the Toxicity Testing in the 21st Century , 2010, Environmental health perspectives.

[11]  P. Biswas,et al.  Concept of Assessing Nanoparticle Hazards Considering Nanoparticle Dosemetric and Chemical/Biological Response Metrics , 2010, Journal of toxicology and environmental health. Part A.

[12]  Jeffrey Fisher,et al.  Interpreting NHANES biomonitoring data, cadmium. , 2010, Toxicology letters.

[13]  Wei Zhang,et al.  Epigenetic Regulation in Particulate Matter-Mediated Cardiopulmonary Toxicities: A Systems Biology Perspective. , 2012, Current pharmacogenomics and personalized medicine.

[14]  Kenny S. Crump,et al.  Calculation of Benchmark Doses from Continuous Data , 1995 .

[15]  Patricia Ruiz,et al.  SAR/QSAR methods in public health practice. , 2011, Toxicology and applied pharmacology.

[16]  D. Dix,et al.  Informing Selection of Nanomaterial Concentrations for ToxCast in Vitro Testing Based on Occupational Exposure Potential , 2011, Environmental health perspectives.

[17]  H. Dosaka-akita,et al.  Pneumoconiosis-related lung cancers: preferential occurrence from diffuse interstitial fibrosis-type pneumoconiosis. , 2000, American journal of respiratory and critical care medicine.

[18]  Peter J Boogaard,et al.  Human biomonitoring as a pragmatic tool to support health risk management of chemicals--examples under the EU REACH programme. , 2011, Regulatory toxicology and pharmacology : RTP.

[19]  L. Lesko,et al.  Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. , 2001, Annual review of pharmacology and toxicology.

[20]  D. Dix,et al.  The ToxCast program for prioritizing toxicity testing of environmental chemicals. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[21]  Thomas A. Louis,et al.  What Role for Biologically Based Dose–Response Models in Estimating Low-Dose Risk? , 2010, Environmental health perspectives.

[22]  Annie M. Jarabek,et al.  CONSIDERATION OF TEMPORAL TOXICITY CHALLENGES CURRENT DEFAULT ASSUMPTIONS , 1995 .

[23]  Melvin E Andersen,et al.  New directions in incidence-dose modeling. , 2005, Trends in biotechnology.

[24]  D. Noble,et al.  Systems Biology: An Approach , 2010, Clinical pharmacology and therapeutics.

[25]  P. Nelson,et al.  Microarray bioinformatics. , 2011, Methods in molecular biology.

[26]  B. Allen,et al.  Evidence-based dose-response assessment for thyroid tumorigenesis from acrylamide. , 2008, Regulatory toxicology and pharmacology : RTP.

[27]  W. Lutz,et al.  Susceptibility differences in chemical carcinogenesis linearize the dose-response relationship: threshold doses can be defined only for individuals. , 2001, Mutation research.

[28]  Aldons J. Lusis,et al.  Metabolic syndrome: from epidemiology to systems biology , 2008, Nature Reviews Genetics.

[29]  Robert J Kavlock,et al.  Computational toxicology--a state of the science mini review. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[30]  D. Wishart Applications of Metabolomics in Drug Discovery and Development , 2008, Drugs in R&D.

[31]  E. Lander,et al.  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease , 2003, Nature Genetics.

[32]  R J Smith,et al.  Methodologic issues in using epidemiologic studies of occupational cohorts for cancer risk assessment. , 1992, Epidemiologia e prevenzione.

[33]  Melvin E. Andersen,et al.  Temporal concordance between apical and transcriptional points of departure for chemical risk assessment. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[34]  B. Allen,et al.  Use of Early Effect Biomarker Data to Enhance Dose-Response Models of Lung Tumors in Rats Exposed to Titanium Dioxide , 2013 .

[35]  P. Borm,et al.  Concordance Between In Vitro and In Vivo Dosimetry in the Proinflammatory Effects of Low-Toxicity, Low-Solubility Particles: The Key Role of the Proximal Alveolar Region , 2008, Inhalation toxicology.

[36]  Roel P F Schins,et al.  Genotoxicity of Poorly Soluble Particles , 2007, Inhalation toxicology.

[37]  L. Stayner,et al.  Rat- and human-based risk estimates of lung cancer from occupational exposure to poorly-soluble particles: A quantitative evaluation , 2009 .

[38]  J. Bailar,et al.  Toxicity Testing in the 21st Century: A Vision and a Strategy , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[39]  G. Churchill,et al.  Statistical design and the analysis of gene expression microarray data. , 2007, Genetical research.

[40]  Michael I. Luster,et al.  A Statistical Model for Assessing Genetic Susceptibility as a Risk Factor in Multifactorial Diseases: Lessons from Occupational Asthma , 2006, Environmental health perspectives.

[41]  Tracey J. Woodruff,et al.  Estimating Risk from Ambient Concentrations of Acrolein across the United States , 2006, Environmental health perspectives.

[42]  Xingming Zhao,et al.  Computational Systems Biology , 2013, TheScientificWorldJournal.

[43]  D. Hattis,et al.  Distributions of Individual Susceptibility among Humans for Toxic Effects: How Much Protection Does the Traditional Tenfold Factor Provide for What Fraction of Which Kinds of Chemicals and Effects? , 1999, Annals of the New York Academy of Sciences.

[44]  Rory B Conolly,et al.  The use of biologically based modeling in risk assessment. , 2002, Toxicology.

[45]  Bruce A. Fowler,et al.  Modification by ALAD of the Association between Blood Lead and Blood Pressure in the U.S. Population: Results from the Third National Health and Nutrition Examination Survey , 2009, Environmental health perspectives.

[46]  J. Samet,et al.  Invited Commentary: Epidemiology and Risk Assessment , 1998 .

[47]  Alan R. Boobis,et al.  IPCS Framework for Analyzing the Relevance of a Cancer Mode of Action for Humans , 2006 .

[48]  Jonathan I Levy,et al.  Science and Decisions: Advancing Risk Assessment , 2010, Risk analysis : an official publication of the Society for Risk Analysis.

[49]  G L Kimmel,et al.  Harmonization of cancer and noncancer risk assessment: proceedings of a consensus-building workshop. , 2001, Toxicological sciences : an official journal of the Society of Toxicology.

[50]  B. Fowler Biomarkers in toxicology and risk assessment. , 2012, Experientia supplementum.

[51]  M. Stephens,et al.  An Animal Protection Perspective On 21st Century Toxicology , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[52]  Melvin E Andersen,et al.  Linear low-dose extrapolation for noncancer health effects is the exception, not the rule , 2011, Critical reviews in toxicology.

[53]  A G Renwick,et al.  Human variability and noncancer risk assessment--an analysis of the default uncertainty factor. , 1998, Regulatory toxicology and pharmacology : RTP.

[54]  Harmonization Project Document No . 2 CHEMICAL-SPECIFIC ADJUSTMENT FACTORS FOR INTERSPECIES DIFFERENCES AND HUMAN VARIABILITY : GUIDANCE DOCUMENT FOR USE OF DATA IN DOSE / CONCENTRATION – RESPONSE ASSESSMENT , 2005 .

[55]  Andrew Maier,et al.  A Bayesian Network Model for Biomarker‐Based Dose Response , 2010, Risk analysis : an official publication of the Society for Risk Analysis.

[56]  Yuri Nikolsky,et al.  Quantitative knowledge-based analysis in compound safety assessment , 2011, Expert opinion on drug metabolism & toxicology.

[57]  Harvey J Clewell,et al.  A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. , 2007, Toxicological sciences : an official journal of the Society of Toxicology.

[58]  N Mantel,et al.  Fundamental carcinogenic processes and their implications for low-dose risk assessment. , 1978, Cancer research.

[59]  E. Kuempel,et al.  Occupational exposure to titanium dioxide , 2011 .

[60]  Steven K. Gibb Toxicity testing in the 21st century: a vision and a strategy. , 2008, Reproductive toxicology.

[61]  Melvin E. Andersen,et al.  New directions in toxicity testing. , 2011, Annual review of public health.

[62]  Melvin E Andersen,et al.  Computational Systems Biology and Dose-Response Modeling in Relation to New Directions in Toxicity Testing , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[63]  V. Vaidya,et al.  Novel technologies for the discovery and quantitation of biomarkers of toxicity. , 2008, Toxicology.

[64]  E. Schadt Molecular networks as sensors and drivers of common human diseases , 2009, Nature.

[65]  Marilyn J Aardema,et al.  Toxicology and genetic toxicology in the new era of "toxicogenomics": impact of "-omics" technologies. , 2002, Mutation research.

[66]  Ipcs,et al.  Biomarkers in risk assessment: validity and validation , 2001 .

[67]  J M Samet,et al.  Epidemiology and risk assessment. , 1998, American journal of epidemiology.

[68]  Philip J. Landrigan,et al.  Biological markers in environmental health research , 1987 .

[69]  Stephen W. Edwards,et al.  Systems biology and mode of action based risk assessment. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.

[70]  A. Horii,et al.  DNA methylation in cancer: a gene silencing mechanism and the clinical potential of its biomarkers. , 2013, The Tohoku journal of experimental medicine.

[71]  Stephen W. Edwards,et al.  Advancing the Next Generation of Health Risk Assessment , 2012, Environmental health perspectives.

[72]  Andrew Maier,et al.  Assessing Biomarker use in Risk Assessment—A Survey of Practitioners , 2004, Journal of toxicology and environmental health. Part A.

[73]  R. Judson,et al.  Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. , 2011, Chemical research in toxicology.

[74]  Ord,et al.  A Review of the Reference Dose and Reference Concentration Processes , 2013 .

[75]  齊藤 宏之,et al.  海外研究紹介 Journal of Occupational and Environmental Hygiene , 2011 .

[76]  Melvin E Andersen,et al.  Toxicity testing in the 21st century: bringing the vision to life. , 2009, Toxicological sciences : an official journal of the Society of Toxicology.

[77]  D Hattis,et al.  Human interindividual variability--a major source of uncertainty in assessing risks for noncancer health effects. , 1994, Risk analysis : an official publication of the Society for Risk Analysis.

[78]  Imran Shah,et al.  Virtual Tissues in Toxicology , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.

[79]  Russell S. Thomas,et al.  Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[80]  J. Loeb,et al.  Systems biology of human epilepsy applied to patients with brain tumors , 2013, Epilepsia.

[81]  Ronald H. White,et al.  State-of-the-Science Workshop Report: Issues and Approaches in Low-Dose–Response Extrapolation for Environmental Health Risk Assessment , 2008, Environmental health perspectives.

[82]  Salomon Sand,et al.  The Benchmark Dose Method—Review of Available Models, and Recommendations for Application in Health Risk Assessment , 2003, Critical reviews in toxicology.

[83]  American Conference Of Governmental Industrial Hygienists 1998 Ventilation A O , 2019 .

[84]  Michael Dourson,et al.  Differential sensitivity of children and adults to chemical toxicity. II. Risk and regulation. , 2002, Regulatory toxicology and pharmacology : RTP.

[85]  Susumu Goto,et al.  KEGG for representation and analysis of molecular networks involving diseases and drugs , 2009, Nucleic Acids Res..

[86]  Janet Woodcock,et al.  Empowering microarrays in the regulatory setting , 2006, Nature Biotechnology.

[87]  Paul A. Schulte,et al.  Molecular epidemiology : principles and practices , 1993 .

[88]  Andrew Maier,et al.  Noncancer Risk Assessment: Principles and Practice in Environmental and Occupational Settings , 2012 .

[89]  M. Sheffer,et al.  CHARACTERIZATION AND APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELS IN RISK ASSESSMENT , 2011 .

[90]  R. Budinsky,et al.  Human and rat primary hepatocyte CYP1A1 and 1A2 induction with 2,3,7,8-tetrachlorodibenzo-p-dioxin, 2,3,7,8-tetrachlorodibenzofuran, and 2,3,4,7,8-pentachlorodibenzofuran. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[91]  G. Oberdörster,et al.  Nanotoxicology: in Vitro–in Vivo Dosimetry , 2012, Environmental health perspectives.

[92]  1986 Part II Environmental Protection Agency Guidelines for Carcinogen Risk Assessment , 2022 .

[93]  R. Weinshilboum,et al.  Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.

[94]  J. Fostel Future of toxicogenomics and safety signatures: balancing public access to data with proprietary drug discovery. , 2007, Pharmacogenomics.

[95]  Conrad Brunk,et al.  Guidelines for the derivation of Biomonitoring Equivalents: report from the Biomonitoring Equivalents Expert Workshop. , 2008, Regulatory toxicology and pharmacology : RTP.

[96]  S. Hays,et al.  Biomonitoring-based risk assessment for hexabromocyclododecane (HBCD). , 2011, International journal of hygiene and environmental health.

[97]  Bruce C Allen,et al.  BMDExpress: a software tool for the benchmark dose analyses of genomic data , 2007, BMC Genomics.

[98]  R. Hertzberg,et al.  A new method for determining allowable daily intakes. , 1986, Fundamental and applied toxicology : official journal of the Society of Toxicology.

[99]  J. Carter,et al.  Effects of particle exposure and particle-elicited inflammatory cells on mutation in rat alveolar epithelial cells. , 1997, Carcinogenesis.

[100]  Heck Hd Noncancer Risk Assessment , 1994 .